Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 2/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4187396 | 0.71 | KEAP1 (0.39) | RBP4KEAP1NFE2L2 | |
| SCHEMBL4172760 | 0.69 | BRD4 (0.32) | BRD4SIGMAR1 | |
| SCHEMBL4967978 | 0.68 | ALDH1A1 (0.46) | RBP4KEAP1NFE2L2CHRM2CHRM1 | |
| SCHEMBL4180019 | 0.67 | POLB (0.33) | BRD4POLBSIGMAR1 | |
| Trifluoroacetic Acid SCHEMBL18422703 | 0.67 | PDK1 (0.41) | BRD4 | |
| Trifluoroacetic Acid SCHEMBL18422700 | 0.67 | PDK1 (0.41) | BRD4 | |
| SCHEMBL4177144 | 0.67 | CHRM2 (0.60) | CHRM2CHRM1CHRM3 | |
| SCHEMBL4176964 | 0.67 | ALDH1A1 (0.51) | KEAP1NFE2L2CHRM2CHRM1CHRM3 | |
| SCHEMBL4966861 | 0.66 | MAPT (0.50) | SIGMAR1 | |
| SCHEMBL4966858 | 0.66 | ROCK2 (0.44) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137623-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-28 | — | — | US | claimed |
| EP-1968980-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2008-09-17 | — | — | EP | claimed |
| WO-2007110782-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-10-04 | — | — | WO | claimed |
| US-20090137623-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137623-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM5 | RBP4 1942/4885KEAP1 2397/4885NFE2L2 1977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.